section name header

Pronunciation ⬇

PRA-zoe-sin

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: peripherally acting antiadrenergics

Indications ⬆ ⬇

BEERS REMS

Unlabeled Use:

Action ⬆ ⬇

  • Dilates both arteries and veins by blocking postsynaptic alpha1-adrenergic receptors.
  • Decreases contractions in smooth muscle of prostatic capsule.
Therapeutic effects:
  • Lowering of BP.
  • Decreased symptoms of prostatic hyperplasia (urinary urgency, urinary hesitancy, nocturia).

Pharmacokinetics ⬆ ⬇

Absorption: 60% absorbed following oral administration.

Distribution: Widely distributed.

Protein Binding: 97%.

Metabolism/Excretion: Extensively metabolized by the liver. Minimal (5–10%) renal excretion of unchanged drug.

Half-Life: 2–3 hr.

Time/Action Profile ⬆ ⬇

(antihypertensive effects)

ROUTEONSETPEAKDURATION
PO2 hr2–4 hr‡10 hr

‡Following single dose; maximal antihypertensive effects occur after 3–4 wk of chronic dosing.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: first-dose orthostatic hypotension, palpitations, angina, edema, syncope

EENT: blurred vision, intraoperative floppy iris syndrome

GI: abdominal cramps, diarrhea, dry mouth, nausea, vomiting

GU: erectile dysfunction, priapism

Neuro: dizziness, headache, weakness, depression, drowsiness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Hypertension

Benign Prostatic Hyperplasia

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Minipress

Code ⬆

NDC Code